• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Epilepsy - Pipeline Review, H2 2013 - Product Image

Epilepsy - Pipeline Review, H2 2013

  • ID: 2634562
  • August 2013
  • 276 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Acorda Therapeutics, Inc.
  • Bio-Link
  • Celentyx Ltd.
  • Eisai Co., Ltd.
  • Knopp Neurosciences Inc.
  • Novartis AG
  • MORE

Epilepsy - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Epilepsy - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Epilepsy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Epilepsy. Epilepsy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Epilepsy.
- A review of the Epilepsy products under development by companies and universities/research institutes based on information derived from company and industry-specific READ MORE >

FEATURED COMPANIES

  • Acorda Therapeutics, Inc.
  • Bio-Link
  • Celentyx Ltd.
  • Eisai Co., Ltd.
  • Knopp Neurosciences Inc.
  • Novartis AG
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Epilepsy Overview
Therapeutics Development
An Overview of Pipeline Products for Epilepsy
Epilepsy Therapeutics under Development by Companies
Epilepsy Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Epilepsy Therapeutics - Products under Development by Companies
Epilepsy Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Epilepsy Therapeutics Development
Kyowa Hakko Kirin Co., Ltd.
Allergan, Inc.
NsGene A/S
Valeant Pharmaceuticals International
Alexza Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc.
Novartis AG
Acorda Therapeutics, Inc.
Chong Kun Dang Pharmaceutical
Eisai Co., Ltd.
H Lundbeck A/S
Pfizer Inc.
UCB Group
Vertex Pharmaceuticals Incorporated
Sun Pharmaceutical Industries Limited
Aeolus Pharmaceuticals, Inc.
GW Pharmaceuticals plc
Anavex Life Sciences Corp.
Ligand Pharmaceuticals Incorporated
Bionomics Limited
Catalyst Pharmaceutical Partners, Inc.
CombinatoRx, Incorporated
Bio-Link
D-Pharm Ltd.
Upsher-Smith Laboratories, Inc.
Snowdon Inc.
Lipicard Technologies Limited
MedGenesis Therapeutix Inc.
Celentyx Ltd.
Concert Pharmaceuticals, Inc.
Knopp Neurosciences Inc.
Biovista Inc.
Asklepios BioPharmaceutical, Inc.
Marinus Pharmaceuticals, Inc.
NeuroTherapeutics Pharma Inc.
Bial - Portela & Ca, S.A.
XERIS Pharmaceuticals, Inc.
MediProPharma, Inc.
Neurelis, Inc.
Vichem Chemie Research Ltd.
Epilepsy - Therapeutics Assessment
Assessment by Monotherapy Products
Drug Profiles
ANAVEX-2-73 - Drug Profile
lacosamide - Drug Profile
lacosamide - Drug Profile
brivaracetam - Drug Profile
perampanel - Drug Profile
perampanel - Drug Profile
perampanel - Drug Profile
carbamazepine - Drug Profile
alprazolam - Drug Profile
ICA-105665 - Drug Profile
Antiepileptic Drugs - Drug Profile
midazolam hydrochloride - Drug Profile
everolimus - Drug Profile
zonisamide - Drug Profile
carisbamate - Drug Profile
carisbamate - Drug Profile
levetiracetam - Drug Profile
levetiracetam - Drug Profile
diazepam - Drug Profile
tonabersat - Drug Profile
GWP-42006 - Drug Profile
fosphenytoin sodium - Drug Profile
ANAVEX-19-144 - Drug Profile
belnacasan - Drug Profile
Drugs Targeting Gamma-Amino Butyric Acid-A Receptor - Drug Profile
YKP-3089 - Drug Profile
naluzotan - Drug Profile
CPP-115 - Drug Profile
NsG-0501 - Drug Profile
DP-VPA - Drug Profile
BGG-492 - Drug Profile
topiramate ER - Drug Profile
ganaxolone - Drug Profile
ezogabine - Drug Profile
rufinamide - Drug Profile
BVA-601 - Drug Profile
Program For Neurological Disorders - Drug Profile
SUN-44 - Drug Profile
AEOL-11207 - Drug Profile
eslicarbazepine acetate - Drug Profile
eslicarbazepine acetate - Drug Profile
C-10068 - Drug Profile
Z-944 - Drug Profile
UX-007 - Drug Profile
Drug For Epilepsy - Drug Profile
diazepam - Drug Profile
topiramate - Drug Profile
INS-001 - Drug Profile
VID-45110 - Drug Profile
verapamil - Drug Profile
Lanthionine-Galanin - Drug Profile
ARA-290 - Drug Profile
Drug For Epilepsy - Drug Profile
BNP-TLE - Drug Profile
Oligonucleotide For Dravet Syndrome - Drug Profile
Drug Targeting Kv7.2 And Kv7.3 - Drug Profile
pregabalin CR - Drug Profile
SL-327 - Drug Profile
GABA Receptor Modulator - Drug Profile
Remegal - Drug Profile
Gene Therapy For Epilepsy - Drug Profile
GABA Agonist - Drug Profile
Dihydroxyflavone - Drug Profile
KM-314 - Drug Profile
KM-113 - Drug Profile
UBP-608 - Drug Profile
Methyl Pentanediol - Drug Profile
diazepam - Drug Profile
SF-0034 - Drug Profile
Potassium Channel Modulator - Drug Profile
diazepam XeriJect - Drug Profile
2-deoxy-D-glucose - Drug Profile
2-deoxy-D-glucose - Drug Profile
IPR-003 - Drug Profile
ADV-6769 - Drug Profile
ADV-5803 - Drug Profile
CKD-903 - Drug Profile
LT-4121 - Drug Profile
LT-4122 - Drug Profile
LT-4123 - Drug Profile
LT-4124 - Drug Profile
LT-4125 - Drug Profile
LT-4126 - Drug Profile
MRS-5474 - Drug Profile
GLX-1112 - Drug Profile
MPP-021 - Drug Profile
MPP-313 - Drug Profile
MPP-315 - Drug Profile
Kv7 Program - Drug Profile
NAX-8102 - Drug Profile
Propofol Hemisuccinate - Drug Profile
Dynamin Inhibitor Program - Drug Profile
NAX-5055 - Drug Profile
Ketamine Analogue - Drug Profile
ADD-405008 - Drug Profile
fosfructose - Drug Profile
Cannabidivarin - Drug Profile
Epilepsy Therapeutics - Drug Profile Updates
Epilepsy Therapeutics - Discontinued Products
Epilepsy Therapeutics - Dormant Products
Epilepsy - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Epilepsy, H2 2013
Products under Development for Epilepsy - Comparative Analysis, H2 2013
Number of Products under Development by Companies, H2 2013
Number of Products under Development by Companies, H2 2013 (Contd..1)
Number of Products under Development by Companies, H2 2013 (Contd..2)
Number of Products under Development by Companies, H2 2013 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H2 2013
Comparative Analysis by Late Stage Development, H2 2013
Comparative Analysis by Mid Clinical Stage Development, H2 2013
Comparative Analysis by Early Clinical Stage Development, H2 2013
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013
Products under Development by Companies, H2 2013
Products under Development by Companies, H2 2013 (Contd..1)
Products under Development by Companies, H2 2013 (Contd..2)
Products under Development by Companies, H2 2013 (Contd..3)
Products under Development by Companies, H2 2013 (Contd..4)
Products under Development by Companies, H2 2013 (Contd..5)
Products under Investigation by Universities/Institutes, H2 2013
Kyowa Hakko Kirin Co., Ltd., H2 2013
Allergan, Inc., H2 2013
NsGene A/S, H2 2013
Valeant Pharmaceuticals International, H2 2013
Alexza Pharmaceuticals, Inc., H2 2013
Neurocrine Biosciences, Inc., H2 2013
Novartis AG, H2 2013
Acorda Therapeutics, Inc., H2 2013
Chong Kun Dang Pharmaceutical, H2 2013
Eisai Co., Ltd., H2 2013
H Lundbeck A/S, H2 2013
Pfizer Inc., H2 2013
UCB Group, H2 2013
Vertex Pharmaceuticals Incorporated, H2 2013
Sun Pharmaceutical Industries Limited, H2 2013
Aeolus Pharmaceuticals, Inc., H2 2013
GW Pharmaceuticals plc, H2 2013
Anavex Life Sciences Corp., H2 2013
Ligand Pharmaceuticals Incorporated, H2 2013
Bionomics Limited, H2 2013
Catalyst Pharmaceutical Partners, Inc., H2 2013
CombinatoRx, Incorporated, H2 2013
Bio-Link, H2 2013
D-Pharm Ltd., H2 2013
Upsher-Smith Laboratories, Inc., H2 2013
Snowdon Inc., H2 2013
Lipicard Technologies Limited, H2 2013
MedGenesis Therapeutix Inc., H2 2013
Celentyx Ltd., H2 2013
Concert Pharmaceuticals, Inc., H2 2013
Knopp Neurosciences Inc., H2 2013
Biovista Inc., H2 2013
Asklepios BioPharmaceutical, Inc., H2 2013
Marinus Pharmaceuticals, Inc., H2 2013
NeuroTherapeutics Pharma Inc., H2 2013
Bial - Portela & Ca, S.A., H2 2013
XERIS Pharmaceuticals, Inc., H2 2013
MediProPharma, Inc., H2 2013
Neurelis, Inc., H2 2013
Vichem Chemie Research Ltd., H2 2013
Assessment by Monotherapy Products, H2 2013
Epilepsy Therapeutics - Drug Profile Updates
Epilepsy Therapeutics - Discontinued Products
Epilepsy Therapeutics - Dormant Products
Epilepsy Therapeutics - Dormant Products (Contd..2)

List of Figures
Number of Products under Development for Epilepsy, H2 2013
Products under Development for Epilepsy - Comparative Analysis, H2 2013
Products under Development by Companies, H2 2013
Products under Investigation by Universities/Institutes, H2 2013
Late Stage Products, H2 2013
Mid Clinical Stage Products, H2 2013
Early Clinical Stage Products, H2 2013
Discovery and Pre-Clinical Stage Products, H2 2013
Assessment by Monotherapy Products, H2 2013 77

Kyowa Hakko Kirin Co., Ltd.
Allergan, Inc.
NsGene A/S
Valeant Pharmaceuticals International
Alexza Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc.
Novartis AG
Acorda Therapeutics, Inc.
Chong Kun Dang Pharmaceutical
Eisai Co., Ltd.
H Lundbeck A/S
Pfizer Inc.
UCB Group
Vertex Pharmaceuticals Incorporated
Sun Pharmaceutical Industries Limited
Aeolus Pharmaceuticals, Inc.
GW Pharmaceuticals plc
Anavex Life Sciences Corp.
Ligand Pharmaceuticals Incorporated
Bionomics Limited
Catalyst Pharmaceutical Partners, Inc.
CombinatoRx, Incorporated
Bio-Link
D-Pharm Ltd.
Upsher-Smith Laboratories, Inc.
Snowdon Inc.
Lipicard Technologies Limited
MedGenesis Therapeutix Inc.
Celentyx Ltd.
Concert Pharmaceuticals, Inc.
Knopp Neurosciences Inc.
Biovista Inc.
Asklepios BioPharmaceutical, Inc.
Marinus Pharmaceuticals, Inc.
NeuroTherapeutics Pharma Inc.
Bial - Portela & Ca, S.A.
XERIS Pharmaceuticals, Inc.
MediProPharma, Inc.
Neurelis, Inc.
Vichem Chemie Research Ltd.

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos